Switch theme
Sign up to access all valuation multiples
Dr. Lal PathLabs Ltd is a pathology lab based in India. It is involved in providing diagnostic services and other healthcare tests in the area of pathology and radiology. The company operates laboratories for carrying out pathological diagnostic services in various branches of biochemistry, hematology, histopathology, microbiology, electrophoresis, immunochemistry, immunology, virology, cytology, and other pathological and radiological investigations. Its diagnostic services assist to prevent, monitor and treat diseases and improving health conditions. The company has business operations in India and other countries, of which maximum revenue is generated within India.
1995
4.1K+
LTM Revenue $294M
LTM EBITDA $82.7M
$2.6B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Dr. Lal PathLabs has a last 12-month revenue (LTM) of $294M and a last 12-month EBITDA of $82.7M.
In the most recent fiscal year, Dr. Lal PathLabs achieved revenue of $288M and an EBITDA of $92.4M.
Dr. Lal PathLabs expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Dr. Lal PathLabs valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $294M | XXX | $288M | XXX | XXX | XXX |
| Gross Profit | $236M | XXX | $232M | XXX | XXX | XXX |
| Gross Margin | 80% | XXX | 80% | XXX | XXX | XXX |
| EBITDA | $82.7M | XXX | $92.4M | XXX | XXX | XXX |
| EBITDA Margin | 28% | XXX | 32% | XXX | XXX | XXX |
| EBIT | $67.4M | XXX | $105M | XXX | XXX | XXX |
| EBIT Margin | 23% | XXX | 36% | XXX | XXX | XXX |
| Net Profit | $55.8M | XXX | $57.0M | XXX | XXX | XXX |
| Net Margin | 19% | XXX | 20% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Dr. Lal PathLabs's stock price is INR 2787 (or $33).
Dr. Lal PathLabs has current market cap of INR 232B (or $2.7B), and EV of INR 222B (or $2.6B).
See Dr. Lal PathLabs trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.6B | $2.7B | XXX | XXX | XXX | XXX | $0.67 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Dr. Lal PathLabs has market cap of $2.7B and EV of $2.6B.
Dr. Lal PathLabs's trades at 9.2x EV/Revenue multiple, and 29.1x EV/EBITDA.
Equity research analysts estimate Dr. Lal PathLabs's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Dr. Lal PathLabs has a P/E ratio of 48.8x.
See valuation multiples for Dr. Lal PathLabs and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.7B | XXX | $2.7B | XXX | XXX | XXX |
| EV (current) | $2.6B | XXX | $2.6B | XXX | XXX | XXX |
| EV/Revenue | 8.8x | XXX | 9.2x | XXX | XXX | XXX |
| EV/EBITDA | 31.4x | XXX | 29.1x | XXX | XXX | XXX |
| EV/EBIT | 38.5x | XXX | 28.1x | XXX | XXX | XXX |
| EV/Gross Profit | 11.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | 48.8x | XXX | 51.1x | XXX | XXX | XXX |
| EV/FCF | 47.6x | XXX | 43.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialDr. Lal PathLabs's last 12 month revenue growth is 12%
Dr. Lal PathLabs's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $31K for the same period.
Dr. Lal PathLabs's rule of 40 is 43% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Dr. Lal PathLabs's rule of X is 57% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Dr. Lal PathLabs and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 12% | XXX | 12% | XXX | XXX | XXX |
| EBITDA Margin | 28% | XXX | 32% | XXX | XXX | XXX |
| EBITDA Growth | 10% | XXX | 4% | XXX | XXX | XXX |
| Rule of 40 | 43% | XXX | 43% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 57% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $31K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 44% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| Integral Diagnostics | XXX | XXX | XXX | XXX | XXX | XXX |
| Sonic Healthcare | XXX | XXX | XXX | XXX | XXX | XXX |
| Bangkok Dusit Medical Services | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Dr. Lal PathLabs acquired XXX companies to date.
Last acquisition by Dr. Lal PathLabs was XXXXXXXX, XXXXX XXXXX XXXXXX . Dr. Lal PathLabs acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Dr. Lal PathLabs founded? | Dr. Lal PathLabs was founded in 1995. |
| Where is Dr. Lal PathLabs headquartered? | Dr. Lal PathLabs is headquartered in India. |
| How many employees does Dr. Lal PathLabs have? | As of today, Dr. Lal PathLabs has 4.1K+ employees. |
| Is Dr. Lal PathLabs publicy listed? | Yes, Dr. Lal PathLabs is a public company listed on NSE. |
| What is the stock symbol of Dr. Lal PathLabs? | Dr. Lal PathLabs trades under LALPATHLAB ticker. |
| When did Dr. Lal PathLabs go public? | Dr. Lal PathLabs went public in 2015. |
| Who are competitors of Dr. Lal PathLabs? | Similar companies to Dr. Lal PathLabs include e.g. Australian Clinical Labs, Healius, Integral Diagnostics, Sonic Healthcare. |
| What is the current market cap of Dr. Lal PathLabs? | Dr. Lal PathLabs's current market cap is $2.7B |
| What is the current revenue of Dr. Lal PathLabs? | Dr. Lal PathLabs's last 12 months revenue is $294M. |
| What is the current revenue growth of Dr. Lal PathLabs? | Dr. Lal PathLabs revenue growth (NTM/LTM) is 12%. |
| What is the current EV/Revenue multiple of Dr. Lal PathLabs? | Current revenue multiple of Dr. Lal PathLabs is 8.8x. |
| Is Dr. Lal PathLabs profitable? | Yes, Dr. Lal PathLabs is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Dr. Lal PathLabs? | Dr. Lal PathLabs's last 12 months EBITDA is $82.7M. |
| What is Dr. Lal PathLabs's EBITDA margin? | Dr. Lal PathLabs's last 12 months EBITDA margin is 28%. |
| What is the current EV/EBITDA multiple of Dr. Lal PathLabs? | Current EBITDA multiple of Dr. Lal PathLabs is 31.4x. |
| What is the current FCF of Dr. Lal PathLabs? | Dr. Lal PathLabs's last 12 months FCF is $54.6M. |
| What is Dr. Lal PathLabs's FCF margin? | Dr. Lal PathLabs's last 12 months FCF margin is 19%. |
| What is the current EV/FCF multiple of Dr. Lal PathLabs? | Current FCF multiple of Dr. Lal PathLabs is 47.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
